Similarly, represented by mutation of the EZH2 protein, epigenetic disorders have been widely observed in acute lymphoblastic leukemia (ALL), non-Hodgkin lymphomas (NHLs) and various cancers originating from B cells malignances [233], while epigenetic mechanisms further participant in the high variability of CD20, the general surface marker expressed by the majority of B cells, which have been broadly demonstrated by treating different malignant B lymphocytes with either DNA methyltransferase inhibitor (DNMTis) or histone deacetylase inhibitors (HDACis) [234–236]. Here, EZH2 is linked to acute lymphoblastic leukemia.